OakChart

Coherus Oncology Inc

CHRSHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

0.5825-0.0584 (-9.11%)
2026-11-12 05:39 CET
Market cap
90.00 USD m
Revenue, TTM
53.64 USD m
Net income, TTM
-134.50 USD m
Free cash flow, TTM
-173.71 USD m
EPS diluted, TTM
-0.97
P/E
-
Compare

Price

CHRS against its 20, 50 and 200-day averages
2050200beatmiss
0.501.001.502.003.1M6.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CHRSclose 0.5820-day 0.9050-day 1.09200-day 1.490.58

77.8% under the 52-week high of 2.62 on 27 Jan 2026. 52-week low 0.57 on 11 Nov 2026. Last 15 sessions, 104.9% high to low

Volume 3.52× normal · the line is the 50-bar volume average

Profile

CHRS
52-week range, 0% of the way up
0.602.62

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan C. Herman, Doug H. Farrar and Stephen C. Glover on September 29, 2010 and is headquartered in Redwood City, CA.

IndexRUT
Employees147
IPONov 06, 2014
Beta1.08
ATR, 14d0.10
Rel volume3.52
Short float11.01%
Insider own25.30%
Inst own33.75%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap90.02M
Enterprise Value75.94M
Income-134.50M
Sales53.64M
Book/sh0.16
Cash/sh0.54
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees147
IPONov 06, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S1.68
P/B3.57
P/C1.08
P/FCF-
EV/EBITDA-
EV/Sales1.42
Quick Ratio1.45
Current Ratio1.51
Debt/Eq2.75
LT Debt/Eq2.68
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.97
EPS next Y-0.76
EPS next Q-0.22
EPS this Y42.16%
EPS next Y16.25%
EPS next 5Y33.25%
EPS past 3/5Y27.14% -
Sales past 3/5Y-41.54% -38.41%
EPS Y/Y TTM38.80%
Sales Y/Y TTM-35.81%
EPS Q/Q16.78%
Sales Q/Q23.36%
EarningsNov 09 AMC
EPS/Sales Surpr.-14.21% -10.24%

Ownership

Insider Own25.30%
Insider Trans0.00%
Inst Own33.75%
Inst Trans-1.14%
ROA-45.23%
ROE-275.17%
ROIC-144.86%
Gross Margin63.30%
Oper. Margin-275.94%
Profit Margin-250.76%
SMA20-35.39%
SMA50-46.75%
SMA200-60.80%
Trades-

Technical

Shs Outstand154.53M
Shs Float115.44M
Short Float11.01%
Short Ratio8.36
Short Interest12.71M
52W High2.62 -77.73%
52W Low0.60 -3.66%
Volatility15.59% 11.09%
ATR (14)0.10
RSI (14)30.34
Beta1.08
Rel Volume3.52
Avg Volume1.52M
Volume5,361,292

Performance

Perf Week-31.49%
Perf Month-45.56%
Perf Quarter-48.90%
Perf Half Y-65.84%
Perf YTD-58.98%
Perf Year-56.85%
Perf 3Y-63.36%
Perf 5Y-96.85%
Perf 10Y-97.89%
Recom1.33
Target Price7.25
Prev Close0.64
Price0.58
Change %-9.11%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 29, 2026ResumedHH.C. WainwrightBuy$7+1,101.7%
May 11, 2026InitiatedGGuggenheimBuy$12+1,960.1%
Jan 23, 2026InitiatedOOppenheimerOutperform$10+1,616.7%
Sep 04, 2025UpgradeMMaxim GroupHold → Buy
Aug 16, 2024DowngradeUUBSBuy → Neutral$4 → $1.50+157.5%
Nov 17, 2023InitiatedRRobert W. BairdOutperform$11+1,788.4%
Nov 08, 2023DowngradeMMaxim GroupBuy → Hold
Jul 24, 2023InitiatedCCitigroupBuy$12+1,960.1%
May 01, 2023InitiatedTTruistBuy$24+4,020.2%
Mar 28, 2023UpgradeUUBSNeutral → Buy$11+1,788.4%

Peers

Mkt cap
TickerCompanyMkt cap
AGENAgenus Inc326.68M
IPHAInnate Pharma ADR177.60M
IOVAIovance Biotherapeutics Inc3.74B
ALXOAlx Oncology Holdings Inc154.87M
SMMTSummit Therapeutics Inc13.27B
CMPXCompass Therapeutics Inc149.51M
ONCBeOne Medicines Ltd ADR44.22B
IMCRImmunocore Holdings plc ADR1.63B
CUECue Biopharma Inc135.55M
PYXSPyxis Oncology Inc196.16M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IWCiShares Micro-Cap ETFAUM: 1.22B
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 200
  • Coherus Misses On Both Lines As Loqtorzi Stalls, Guidance Is Cut And A Going-Concern Warning Overshadows An Esophageal Signal (Earnings Whispers) +6.18% -21.61%
  • Coherus Oncology: Q3 Earnings Snapshot (Associated Press)
  • Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan (GlobeNewswire)
  • Coherus Needs Loctorsi Growth And A Udenica Milestone To Steady A Sub-Dollar Stock (Earnings Whispers) -9.72% +7.50%
  • Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development (GlobeNewswire) +8.41% -22.55%
  • Coherus to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.94%
  • Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 (GlobeNewswire)
  • Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026 (GlobeNewswire)
  • Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets (GlobeNewswire)
  • Coherus to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights (GlobeNewswire) +16.52%
  • Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ... (GuruFocus.com) -12.76%
  • Coherus Oncology: Q2 Earnings Snapshot (Associated Press)
  • Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.250-0.219-0.25014.2715.905
2026Q22026-08-05-0.220-0.250-0.13114.3114.415
2026Q12026-05-11-0.270-0.263-0.27812.3114.223
2025Q42026-03-09-0.390-0.355-0.31012.7513.915
2025Q32025-11-06-0.310-0.354-0.30211.5713.364
2025Q22025-08-07-0.390-0.220-0.35610.259.354
2025Q12025-05-12-0.410-0.297-0.4887.6054.673
2024Q42025-03-10-0.440-0.306-0.43954.1444.155
2024Q32024-11-06-0.090-0.163-0.09370.7758.985
2024Q22024-08-08-0.110-0.249-0.11365.0062.065
2024Q12024-05-090.830-0.2540.82077.0681.703
2023Q42024-03-13-0.710-0.207-0.71491.5296.8910
2023Q32023-11-06-0.410-0.390-0.40674.5781.789
2023Q22023-08-02-0.490-0.629-0.49158.7250.478
2023Q12023-05-08-0.960-0.721-0.95532.4046.295
2022Q42023-03-06-0.760-0.982-0.75545.3547.695

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.2301.3991.228356.07357.25
2020FY1.6201.7201.624475.82480.32
2021FY-3.810-3.617-3.805326.55335.74
2022FY-3.760-3.618-3.758211.04213.31
2023FY-2.530-1.939-2.526257.24262.8
2024FY0.2500.353-1.293266.96256.37
2025FY-1.560-1.537-1.56042.1743.47
2026FY--0.902--58.46
2027FY--0.756--92.89
2028FY--0.464--146.85
2029FY-0.059--250.84
2030FY-0.297--355.08

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1060316.7415.5018.90
2026Q4S2026-11-0960117.8116.5019.28
2026Q4S2026-10-2860117.8116.5019.28
2026Q4S2026-10-2760117.8216.5019.28
2026Q4S2026-10-2160018.2216.5021.71
2026Q4S2026-10-2060118.2216.5021.71
2026Q4S2026-08-1460218.2216.5021.71
2026Q4S2026-08-0770318.1316.5021.71
2026Q4S2026-08-0670218.2016.5021.71
2026Q4S2026-07-2660118.5516.5023.70
2026Q4S2026-06-1860518.5516.5023.70
2026Q4S2026-05-2760518.5516.5023.70
2026Q4S2026-05-2460418.7716.5025.00
2026Q4S2026-05-1261418.7716.5025.00

Estimate history

EPS, annual-4.48-3.2191.2281.624-3.805-3.758-2.526-1.293-1.454-0.9705
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.093-0.439-0.488-0.356-0.302-0.31-0.278-0.131-0.251
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1.5560356.071475.824326.551211.042257.24426.38942.17253.64
Period201720182019202020212022202320242025TTM
Sales, quarterly70.77454.1447.59910.25411.57112.74812.3114.30714.274
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual59.8468.30370.36772.51376.9378.852112.215115.615121.155154.535
Period201720182019202020212022202320242025MRQ
Shares, quarterly115.213115.615115.907116.223116.236121.155154.218154.47154.535
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue53.6442.1726.39257.24211.04326.55475.82356.070.00
Cost of Goods Sold Incl. D&A19.6817.7414.00162.7873.7861.0540.5520.343.23
Gross Profit33.9524.4312.3994.46137.26265.51435.27335.73-3.23
Selling, General and Administrative Excl. Other181.97203.97205.27287.66394.14529.36278.95227.86197.32
Research and Development93.07104.9686.56102.05195.66359.65139.8790.82106.38
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-148.01-179.53-192.88-193.20-256.88-263.86156.32107.88-200.56
Interest Expense9.549.0010.7340.5432.4722.9621.1717.609.68
Unusual Expense3.360.8019.4010.006.220.000.000.070.63
Net Income Before Taxes-155.50-183.12-215.39-238.27-291.75-287.10135.7192.78-209.41
Income Taxes0.000.000.00-0.380.000.003.462.940.00
Consolidated Net Income-155.50-183.12-215.39-237.89-291.75-287.10132.2489.83-209.41
Net Income From Continuing Operations-155.50-183.12-215.39-237.89-291.75-287.10132.2489.83-209.34
Net Income-134.50-170.29-148.08-237.89-291.75-287.10132.2489.83-209.34
EPS (Recurring)-0.85-1.45-1.17-2.45-3.70-3.811.621.23-3.21
EPS (Basic, Before Extraordinaries)-0.97-1.45-1.29-2.53-3.76-3.811.851.29-3.22
EPS (Diluted)-0.97-1.45-1.29-2.53-3.76-3.811.621.23-3.22
EBITDA-144.52-175.61-187.60-189.41-253.18-258.20161.29111.14-197.32
Non-Operating Income (Expense)5.416.217.625.473.82-0.280.552.571.46
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.4316.9727.8034.0650.7451.3627.8624.5234.80
Price To Earnings Ratio------10.9515.46-
Price To Sales Ratio3.503.945.991.222.913.693.053.70-
Gross Margin63.3057.9446.9436.7265.0481.3191.4894.29-
Operating Margin-275.94-425.72-730.91-75.10-121.72-80.8032.8530.30-
Net Margin-250.76-403.80-561.15-92.48-138.24-87.9227.7925.23-
Shares Outstanding154.53121.15115.61112.2278.8576.9372.5170.3768.30
Market Capitalization90.0090.00158.99370.84616.001,225.491,252.191,262.67615.63

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue14.2714.3112.3112.7511.5710.257.6054.14
Cost of Goods Sold Incl. D&A4.955.104.704.944.694.413.7034.89
Gross Profit9.339.207.627.816.885.843.9019.25
Selling, General and Administrative Excl. Other42.9841.5343.7753.6949.1251.3349.3454.83
Research and Development21.7520.5820.6630.0826.2925.2923.3120.20
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-33.65-32.33-36.15-45.88-42.23-45.49-45.44-35.58
Interest Expense2.782.322.192.252.332.282.155.35
Unusual Expense3.360.000.000.002.100.000.006.67
Net Income Before Taxes-38.88-33.35-36.94-46.35-44.52-44.86-47.40-50.70
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-38.88-33.35-36.94-46.35-44.52-44.86-47.40-50.70
Net Income From Continuing Operations-38.88-33.35-36.94-46.35-44.52-44.86-47.40-50.70
Net Income-38.97-20.32-37.94-37.28-35.11-41.34-56.57-50.70
EPS (Recurring)-0.24-0.13-0.28-0.31-0.29-0.36-0.49-0.40
EPS (Basic, Before Extraordinaries)-0.25-0.13-0.28-0.31-0.30-0.36-0.49-0.44
EPS (Diluted)-0.25-0.13-0.28-0.31-0.30-0.36-0.49-0.44
EBITDA-32.80-31.47-35.27-44.98-41.27-44.47-44.39-34.54
Non-Operating Income (Expense)0.921.311.401.782.142.900.19-3.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.682.582.382.783.395.425.375.04
Price To Earnings Ratio------4.63-
Price To Sales Ratio3.504.264.924.052.280.590.470.60
Gross Margin65.3664.3361.8661.2459.4956.9851.3235.56
Operating Margin-235.74-225.98-293.67-359.90-364.99-443.59-597.91-65.71
Net Margin-272.99-142.03-308.20-292.42-303.42-403.11-744.43-93.63
Shares Outstanding154.53154.47154.22121.15116.24116.22115.91115.61
Market Capitalization90.00215.95253.31171.64190.6184.7893.53158.99

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments172.12125.99117.75191.68417.19541.16177.6772.41126.97
Short Term Receivables18.42122.33260.52109.96123.02157.05141.990.000.00
Inventories3.174.2162.6038.7937.6444.239.811.660.00
Other Current Assets12.9989.0634.7640.8024.4625.0413.5410.3718.51
Total Current Assets206.71341.58475.63381.23602.32767.48343.0184.43145.48
Net Property, Plant & Equipment4.307.0911.0314.4416.0120.0616.496.6612.77
Total Investments and Advances0.000.000.450.440.440.440.240.790.79
Intangible Assets46.2453.6571.675.933.563.563.563.563.56
Deferred Tax Assets7.436.32-------
Other Assets1.1046.2170.8278.8057.0050.1045.634.030.01
Total Assets265.77454.85629.60480.85679.33841.65408.9399.47162.61
Short Term Debt Incl. Current Port. of LT Debt1.832.842.154.323.493.132.200.000.00
Accounts Payable9.9128.4635.2211.5316.1615.2025.9815.2915.71
Other Current Liabilities128.64251.69294.41122.85145.68127.3286.7917.9712.68
Total Current Liabilities140.39282.98331.77138.69165.33145.65114.9733.2628.39
Long Term Debt52.54295.81478.70476.10415.53414.85188.64103.09101.61
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities8.537.421.10------
Other Liabilities3.310.6311.463.470.750.180.101.712.07
Total Liabilities204.76586.84823.03618.26581.61560.67303.71138.06132.08
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity61.01-131.99-193.43-137.4297.73280.97105.21-38.5931.82
Total Shareholders Equity61.01-131.99-193.43-137.4297.73280.97105.21-38.5931.82
Accumulated Minority Interest0.000.000.000.000.000.000.000.00-1.29
Total Equity61.01-131.99-193.43-137.4297.73280.97105.21-38.5930.54
Total Liabilities & Stockholders Equity265.77454.85629.60480.85679.33841.65408.9399.47162.61
Book Value Per Share0.50-1.14-1.72-1.741.273.871.50-0.560.53
Tangible Book Value Per Share0.12-1.61-2.36-1.821.223.831.44-0.620.47
Full-Time Employees147228306359332317291232122
Price to Book Ratio3.57-1.81-2.72-6.3412.564.4912.04-16.029.07
Return on Assets-50.82-39.72-42.85-50.29-37.7521.1535.34-159.75-139.65
Return on Equity-----151.6268.49269.68--909.90
Return on Invested Capital-149.97-90.39-83.39-86.14-55.9419.0130.57-324.55-178.50
Quick Ratio1.451.191.242.473.424.972.902.495.12
Current Ratio1.471.211.432.753.645.272.982.545.12

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-135.94168.0228.51-237.89-291.75-287.10132.2489.83-209.41
Depreciation3.493.925.283.793.705.664.973.263.23
Other Funds (Non Cash)2.49-304.62-110.1296.04126.19201.6549.4149.1936.61
Funds from Operations-129.95-132.67-76.33-138.06-161.87-79.79186.62142.28-169.56
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-43.76-5.8455.89-36.83-79.2642.36-32.48-113.9310.30
Cash from Operating Activities-173.71-138.51-20.44-174.88-241.12-37.43154.1528.36-159.27
Capital Expenditures0.000.000.00-0.29-2.04-1.29-7.23-1.82-0.79
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-0.70
Sale of Fixed Assets and Businesses470.31470.31227.820.840.000.000.170.00-
Purchase or Sale of Investments59.33-82.3814.89138.13-127.38-1.120.150.160.30
Purchase of Investments-64.61-103.840.00-19.51-127.38-182.49-273.85-20.23-42.87
Sale Or Maturity of Investments123.9421.4614.89157.640.00181.36274.0020.4043.17
Other Uses-1.11-12.84-12.50-1.05-37.43-136.00-7.50-11.070.00
Other Sources-478.680.000.117.000.000.000.000.000.00
Cash from Investing Activities49.84375.09230.32144.64-166.85-138.41-14.40-12.73-1.19
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock61.918.252.3874.229.3754.3021.2317.23105.42
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock61.918.252.3874.229.3754.3021.2317.23105.42
Proceedsfrom Stock Options61.918.252.3873.538.6843.913.8011.67103.34
Issuance or Reduction of Debt, Net11.88-233.19-223.410.0049.93-0.67221.7772.950.00
Change in Long Term Debt11.88-233.19-223.410.0049.93-0.67221.7772.950.00
Issuance of Long Term Debt52.660.0036.980.00240.680.00222.1672.950.00
Reduction of Long Term Debt-40.78-233.19-260.390.00-190.75-0.67-0.390.000.00
Net Financing Active Other Cash Flow0.07-48.7734.05-4.62-4.97-1.75-19.05-0.810.00
Other Financing Activities Uses0.02-48.77-2.48-4.62-4.97-1.75-19.05-0.810.00
Cash from Financing Activities73.86-273.70-186.9769.6054.3351.88223.9589.37105.42
Exchange Rate Effect-----0.000.00-0.280.47
Net Change in Cash-50.01-37.1322.9139.36-353.65-123.96363.69104.72-54.56
Free Cash Flow-173.71-138.51-20.44-175.17-243.16-38.72146.9126.53-160.06
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow------9.8849.66-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments83.63105.31167.05172.12191.66237.64
Short Term Receivables13.9214.2522.5118.42250.50119.64
Inventories4.825.674.833.172.054.51
Other Current Assets11.768.5611.6512.9916.7518.42
Total Current Assets114.13133.79206.03206.71460.95380.20
Net Property, Plant & Equipment0.650.861.094.301.631.91
Total Investments and Advances0.100.000.000.000.000.00
Intangible Assets44.3644.9945.6146.2449.4852.31
Deferred Tax Assets---7.43--
Other Assets11.8611.5413.281.104.455.04
Total Assets171.10191.18266.02265.77516.52439.46
Short Term Debt Incl. Current Port. of LT Debt1.951.951.901.831.791.76
Accounts Payable14.5113.1711.489.9124.8937.62
Other Current Liabilities59.1860.40118.95128.64345.61224.25
Total Current Liabilities75.6475.51132.33140.39372.30263.63
Long Term Debt67.6052.2352.4752.5452.5352.37
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities1.101.101.108.531.101.10
Other Liabilities1.511.501.493.312.822.53
Total Liabilities145.85130.34187.40204.76428.75319.64
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity25.2560.8478.6261.0187.77119.83
Total Shareholders Equity25.2560.8478.6261.0187.77119.83
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity25.2560.8478.6261.0187.77119.83
Total Liabilities & Stockholders Equity171.10191.18266.02265.77516.52439.46
Book Value Per Share0.160.390.510.500.761.03
Tangible Book Value Per Share-0.120.100.210.120.330.58
Full-Time Employees145--147--
Price to Book Ratio3.572.753.361.881.59-0.46
Return on Assets-45.23-51.10-54.20-50.82-36.70-27.59
Return on Equity-275.17-178.39----860.65
Return on Invested Capital-41.97-17.97-28.94-32.83-25.02-24.00
Quick Ratio1.451.701.521.451.231.43
Current Ratio1.511.771.561.471.241.44

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-39.33-20.63-38.33-37.64-35.53297.77
Depreciation0.850.860.880.900.971.02
Other Funds (Non Cash)8.16-9.603.240.69-2.38-321.76
Funds from Operations-30.32-29.37-34.20-36.06-36.95-22.98
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.70-32.72-23.6816.34-9.39-23.65
Cash from Operating Activities-34.02-62.09-57.89-19.72-46.34-46.63
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00470.310.000.00
Purchase or Sale of Investments-7.6129.6431.755.55-67.20-20.73
Purchase of Investments-30.06-13.90-6.39-14.26-68.85-20.73
Sale Or Maturity of Investments22.4543.5438.1319.811.650.00
Other Uses0.00-0.01-1.09-0.01-0.034.68
Other Sources0.000.000.00-478.680.00478.68
Cash from Investing Activities-7.6129.6330.66-2.84-67.23462.64
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.2053.658.060.000.19
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.2053.658.060.000.19
Proceedsfrom Stock Options0.000.2053.658.060.000.19
Issuance or Reduction of Debt, Net12.00-0.120.000.000.00-233.19
Change in Long Term Debt12.00-0.120.000.000.00-233.19
Issuance of Long Term Debt52.660.000.000.000.000.00
Reduction of Long Term Debt-40.66-0.120.000.000.00-233.19
Net Financing Active Other Cash Flow0.050.06-0.060.020.00-48.53
Other Financing Activities Uses0.110.00-0.110.020.00-48.53
Cash from Financing Activities12.050.1453.598.080.00-281.52
Net Change in Cash-29.58-32.3126.36-14.47-113.56134.48
Free Cash Flow-34.02-62.09-57.89-19.72-46.34-46.63

Revenue breakdown

Product and Service, Other2024: 7.26M 2025: 1.34M
Toripalimab2024: 19.13M 2025: 40.84M
United States2024: 26.39M 2025: 42.17M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.01%12.7M115.4M1.40M
2026-10-1510.79%12.5M115.4M1.22M
2026-09-3020.22%23.3M115.4M1.11M
2026-09-1519.80%22.8M115.4M991.11K
2026-08-3120.72%23.9M115.4M998.02K
2026-08-1420.80%24.0M115.4M955.39K
2026-07-3121.12%24.5M116.1M1.02M
2026-07-1520.61%23.9M115.9M1.15M
2026-06-3022.41%26.0M115.9M1.11M
2026-06-1522.12%25.6M115.9M1.15M
2026-05-2924.00%27.9M116.1M1.29M
2026-05-1524.21%28.1M116.1M1.33M
2026-04-3022.04%27.8M126.2M1.46M
2026-04-1522.00%28.0M127.2M2.13M
2026-03-3124.00%28.1M117.3M2.27M
2026-03-1323.90%28.0M117.3M2.15M
2026-02-2723.65%27.7M116.9M2.04M
2026-02-1325.32%29.6M116.9M1.99M
2026-01-3031.29%29.6M94.6M1.86M
2026-01-1528.90%29.7M102.9M1.18M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.900.550.0001.000.000.718-0.0040.000
call1.000.000.050.093.7196580.000.292-0.0070.000
call1.500.000.250.035.4793,3760.000.246-0.0090.000
call2.000.000.050.056.3764,2290.000.226-0.0100.000
call3.000.000.050.036.7191,3600.000.197-0.0100.000
call4.000.000.050.057.4494930.000.187-0.0110.000
call5.000.000.250.058.8551290.000.191-0.0120.000
put0.500.001.000.052.53445.000.00-0.282-0.0040.000
put1.000.050.600.357.80175.000.00-0.708-0.0070.000
put1.500.451.450.7524.8514010.00-0.754-0.0090.000
put2.001.002.000.900.0001,1600.00-0.774-0.0100.000
put3.002.003.000.000.0000.000.00-0.793-0.0110.000
put4.003.004.000.000.0000.000.00-0.803-0.0110.000
put5.004.005.000.000.0000.000.00-0.809-0.0120.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-298-KCurrent report2026-10-28SEC
2026-08-288-KCurrent report2026-08-28SEC
2026-08-28424B5SEC
2026-08-28424B3SEC
2026-08-178-KCurrent report2026-08-17SEC
2026-08-178-KCurrent report2026-08-17SEC
2026-08-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-27SCHEDULE 13GSEC
2026-06-158-KCurrent report2026-06-12SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-018-KCurrent report2026-05-27SEC
2026-05-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-11SCHEDULE 13G/ASEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-05-05DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Timothy G. Youngquist 2020 Irrevocable Trust8.45%
BlackRock, Inc.7.78%
VANGUARD CAPITAL MANAGEMENT LLC3.86%
Samsara BioCapital, LLC2.22%
GEODE CAPITAL MANAGEMENT, LLC2.01%
Kohlberg Kravis Roberts & Co. L.P.1.97%
STATE STREET CORP1.54%
TWO SIGMA INVESTMENTS, LP1.46%
CM Management, LLC1.36%
C WorldWide Group Holding A/S1.25%

Funds

Fund% owned
iShares Russell 2000 ETF2.09%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.11%
Fidelity Small Cap Index Fund0.92%
BlackRock Advantage Small Cap Core Fund0.60%
Nomura Healthcare Fund0.58%
Fidelity Extended Market Index Fund0.49%
VANGUARD RUSSELL 2000 INDEX FUND0.48%
iShares Russell 2000 Value ETF0.48%
Schwab U.S. Small-Cap ETF0.45%
VANGUARD EXTENDED MARKET INDEX FUND0.38%

OakChart. CHRS. Cached 15 minutes.

Some panels did not load: insider.